
(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
IDF destroys Hezbollah rocket launcher used in large rocket salvo towards Haifa, Galilee - 2
I went to Japan during peak cherry blossom season and found an easy way to escape the crowds at popular tourist attractions - 3
Figure out How to Adjust Your Handshake to Various Societies - 4
How did humans evolve, and will we evolve more? - 5
Massive supernova explosion may have created a binary black hole
Greenland’s melting ice and landslide-prone fjords make the oil and minerals Trump is eyeing dangerous to extract
Ringleader of suspected human trafficking network arrested in Ethiopia
American tourists left stranded in the Caribbean following flight cancellations after airspace closed for Maduro operation
When preventable infections turn deadly behind bars | The Excerpt
Faulty glucose monitors linked to 7 deaths and more than 700 injuries, FDA warns
Israeli Chief of Staff declares new border with Gaza Strip
The Best 20 Tunes that Characterized an Age
4 African Vacationer Locations
'Everyone in this prison has had family killed or shot'













